Pubblicazioni

Cardiologia e U.T.I.C., S.C.

2022

2021

2020

2019

2017

2016

2015

2014

2013

2012

2011

2010

      2009

      2008

      2007

      • Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP MD, Thorsten Lawrenz T, Boriani GD, Estes III NAM, Favale S, Piccininno M, Winters SL, Santini M, MD, Betocchi S, MD, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Prevention of sudden cardiac death and selection of patients for implantable cardioverter-defibrillators in hypertrophic cardiomyopathy. JAMA 2007;298:405-12
      • Spirito P, Autore C. Apical hypertrophic cardiomyopathy or left ventricular noncompaction? A difficult differential diagnosis. Eur Heart J 2007;28:1923-24
      • Cha Y-M, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen W-K. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovascular Electrophysiology 2007; 18:483-7
      • Derchi G. et al. Eelectrocardiographic changes in thalassemia major patients: correlations with myocardial iron overload and myocardial fibrosis. Journal of Cardiovascular Magnetic Resonance 2007 p. 167 Vol 9; N.2

      2006

      • Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ.  Prevalence, clinical profile and significance of the end-stage phase in a large hypertrophic cardiomyopathy cohort.
        Circulation. 2006;114:216-25
      • Spirito P, Autore C.
        Management of hypertrophic cardiomyopathy.
        British Medical Journal. 2006;332:1251-55
      • Mazzotta G.: Il ruolo della proteina C reattiva nelle strategie di prevenzione
        cardiovascolare. Monaldi Arch. Chest Dis 2006; 1, suppl. 2, 55
      • Capuano V, Mazzotta G.: The third component of the complement (C3) is a marker of the risk of atherogenesis.
        European Journal of Cardiovascular Prevention and Rehabilitation, 13:658-660, 2006

      2005

      • Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005 Jan 27;352(4):362-72
      • Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005 Apr 5;45(7):1076-80
      • JambriK Z, Derchi G, et al Lack of prognostic value of normalized integrated backscatter analysis of myocardium in patients with thalassemia major: a long-term follow-up study. Echocardiography 2005 Mar;22(3):239-44
      • Derchi G et al. Efficacy and safety of sildenafil in the treatment of severepulmonary hypertension in patients with hemoglobinopathies. Haematologica2005 Apr;90(4):452-8
      • Derchi et al. LINEE GUIDA PER LE COMPLICANZE CARDIACHE NELLA TALASSEMIA MAJOR Idelson-Gnocchi editori
      • Derchi G et al. Incidence of Pulmonary Hypertension in Haemoglobinopathic Patients without Left Ventricular Dysfunction.  Blood,106(11), November 16, 2005
      • Derchi G, Forni GL. Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies. Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Ann. N.Y. Acad. Sci. 1054: 471-475 (2005). © 2005 New York Academy of Sciences
      • Grupo de Trabajo y Comitè ESC (G. Mazzotta en Comitè y Coordinador de revision de las CPG):Guias de Practica Clinica sobre el diagnostico y tratamiento de la hipertension arterial pulmonar. Rev. Esp. Cardiol 58, 523, 2005
      • G. Mazzotta, S. Pirelli, M. Guazzi, A Barsotti.  Programma di aggiornamento della Federazione Italiana di Cardiologia; 6 fascicoli nel 2005. Centro Scientifico Editore, Torino
      • Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin YLopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K; ESC Committe for Practice Guideline (CPG).  Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J. 2005 Feb;26(4):384-416
      • Derchi G et al Prognostic value of the Atrial Natriuretic Peptide in Asymptomatic Patients with Beta-Thalassemia Major: a ten year follow-up JCM in press

      2004

      • Boriani G, Maron BJ, Shen WK, Spirito P.  Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation. 2004 Oct 12;110(15):e438-42
      • Boriani G, Biffi M, Rapezzi C, Coccolo F, Branzi A, Spirito P. Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter defibrillator. Int J Cardiol. 2004 Oct;97(1):143-4
      • Autore C, Spirito P. Approach to Hypertrophic Cardiomyopathy. Curr Treat Options Cardiovasc Med. 2004 Dec;6(6):489-498
      Azioni sul documento